Effectiveness and Safety of Intermittent Fasting in People with Insulin-Treated Type 2 Diabetes
Diabetes Care: Published on December 2022
With the numbers of people with
type 2 diabetes rising worldwide, dietary modifications provide an essential
therapeutic approach for blood glucose, weight, and cardiovascular risk-factor
management.
Intermittent fasting (IF) has
emerged as an alternative to classic daily caloric reduction. The approaches to
IF range from limiting food consumption to certain hours of the day to
alternate-day fasting.
TAKE-HOME MESSAGE
This randomized controlled trial
assessed the effectiveness of intermittent fasting 3 days a week in patients
with type 2 diabetes on basal insulin treatment. By the 3-month follow-up, the
intermittent fasting group achieved significantly lower HbA1c, daily insulin
dose, and weight from baseline levels compared with the control group.
No serious adverse outcomes or
severe hypoglycemic events occurred.
Intermittent fasting 3 days a week
was associated with greater weight loss and reduction in HbA1c without an
increased risk of hypoglycemia compared with a standard diet.
CONCLUSIONS
IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.
Doctors Liked to Read More
OBJECTIVE
To investigate the safety and
feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over
12 weeks in participants with insulin-treated type 2 diabetes.
RESEARCH DESIGN AND METHODS
Forty-six people were randomized to
an IF or control group. Dietary counseling and continuous glucose monitoring
was provided. Coprimary end points were the change in HbA1c from baseline to 12
weeks and a composite end point (weight reduction ≥2%, insulin dose reduction
≥10%, and HbA1c reduction ≥3 mmol/mol).
RESULTS
The IF group showed a significant
HbA1c reduction compared with the control group over 12 weeks. The coprimary
end point was achieved by 8 people in the IF and none in the control group. No
severe hypoglycemia occurred.
CONCLUSIONS
IF is a safe and feasible dietary
option to ameliorate glycemic control while reducing total daily insulin dose
and body weight in insulin-treated people with type 2 diabetes.
Comments
You must login to write comment